Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once-Daily Treatment With the Long-Acting Glucagon-Like Peptide 1 Analog Liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial

Controlled Trial ◽

Double Blind ◽

Once Daily ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Long Acting

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2008.03.018 ◽

2008 ◽

Vol 81 (2) ◽

pp. 161-168 ◽

Cited By ~ 79

Author(s):

Y. Seino ◽

M.F. Rasmussen ◽

M. Zdravkovic ◽

K. Kaku

Keyword(s):

Type 2 Diabetes ◽

Weight Gain ◽

Controlled Trial ◽

Japanese Patients ◽

Double Blind ◽

Once Daily ◽

Randomized Controlled ◽

Dose Dependent

Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial

Journal of Dermatological Treatment ◽

10.1080/09546634.2020.1826392 ◽

2020 ◽

pp. 1-7

Author(s):

Lu Lin ◽

Xiangjin Xu ◽

Yunjie Yu ◽

Hongjiang Ye ◽

Xiaoqiong He ◽

...

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

10.1111/dom.12802 ◽

2016 ◽

Vol 19 (2) ◽

pp. 200-207 ◽

Cited By ~ 17

Author(s):

Michael A. Nauck ◽

Melanie Kahle ◽

Oleg Baranov ◽

Carolyn F. Deacon ◽

Jens J. Holst

Keyword(s):

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Dipeptidyl Peptidase 4 ◽

Randomized Controlled ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Glucagon Like Peptide ◽

Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial

American Journal of Clinical Nutrition ◽

10.3945/ajcn.115.117440 ◽

2015 ◽

Vol 103 (1) ◽

pp. 66-70 ◽

Cited By ~ 46

Author(s):

Sony S Thazhath ◽

Tongzhi Wu ◽

Michelle J Bound ◽

Helen L Checklin ◽

Scott Standfield ◽

...

Keyword(s):

Type 2 Diabetes ◽

Gastric Emptying ◽

Glycemic Control ◽

Controlled Trial ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Salba-chia (Salvia hispanica L.) in the treatment of overweight and obese patients with type 2 diabetes: A double-blind randomized controlled trial

Nutrition Metabolism and Cardiovascular Diseases ◽

10.1016/j.numecd.2016.11.124 ◽

2017 ◽

Vol 27 (2) ◽

pp. 138-146 ◽

Cited By ~ 36

Author(s):

V. Vuksan ◽

A.L. Jenkins ◽

C. Brissette ◽

L. Choleva ◽

E. Jovanovski ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Obese Patients ◽

Double Blind ◽

Salvia Hispanica ◽

Randomized Controlled ◽

Salvia Hispanica L

Phytosterols and inulin-enriched soymilk increases glucagon-like peptide-1 secretion in healthy men: double-blind randomized controlled trial, subgroup study

BMC Research Notes ◽

10.1186/s13104-018-3958-5 ◽

2018 ◽

Vol 11 (1) ◽

Cited By ~ 1

Author(s):

Noppadol Kietsiriroje ◽

Krisana Kanjanahirun ◽

Jirateep Kwankaew ◽

Ratikorn Ponrak ◽

Supamai Soonthornpun

Keyword(s):

Controlled Trial ◽

Double Blind ◽

Healthy Men ◽

Randomized Controlled ◽

Glucagon Like Peptide ◽

Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double‐blind randomized controlled trial ( BEGIN : ADD TO GLP ‐1 S tudy)

10.1111/dom.12661 ◽

2016 ◽

Vol 18 (7) ◽

pp. 663-670 ◽

Cited By ~ 14

Author(s):

V. R. Aroda ◽

T. S. Bailey ◽

B. Cariou ◽

S. Kumar ◽

L. A. Leiter ◽

...

Keyword(s):

Type 2 Diabetes ◽

Controlled Trial ◽

Insulin Degludec ◽

Double Blind ◽

Randomized Controlled

The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study

10.1111/j.1463-1326.2011.01366.x ◽

2011 ◽

Vol 13 (5) ◽

pp. 418-425 ◽

Cited By ~ 63

Author(s):

G. E. Umpierrez ◽

T. Blevins ◽

J. Rosenstock ◽

C. Cheng ◽

J. H. Anderson ◽

...

Keyword(s):

Type 2 Diabetes ◽

Blind Study ◽

Double Blind Study ◽

Obese Patients ◽

Double Blind ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Long Acting

Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes

Diabetic Medicine ◽

10.1111/dme.12828 ◽

2015 ◽

Vol 33 (2) ◽

pp. 224-230 ◽

Cited By ~ 36

Author(s):

M. A. Bethel ◽

P. Harrison ◽

H. Sourij ◽

Y. Sun ◽

L. Tucker ◽

...

Keyword(s):

Type 2 Diabetes ◽

Platelet Reactivity ◽

Controlled Trial ◽

Once Daily ◽

Randomized Controlled ◽

Daily Aspirin

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

10.1111/dom.12382 ◽

2014 ◽

Vol 16 (12) ◽

pp. 1257-1264 ◽

Cited By ~ 62

Author(s):

J. Reusch ◽

M. W. Stewart ◽

C. M. Perkins ◽

D. T. Cirkel ◽

J. Ye ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Receptor Agonist ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽